Generic Name and Formulations:
Griseofulvin 125mg, 250mg; ultramicrosize; scored tabs.
Bausch Health Companies Inc.
Indications for GRIS-PEG:
Ringworm infections of the skin, scalp, and nails.
375mg daily as 1 or more divided doses; max 750mg daily.
<2 yrs: not recommended. 35-60lbs: 125–187.5mg daily. >60lbs: 187.5mg–375mg daily.
Porphyria. Hepatocellular failure. Pregnancy.
Continue therapy until infection is eradicated. Periodic monitoring of renal, hepatic, and hematopoietic functions. Discontinue if granulocytopenia occurs. Penicillin sensitivity. Avoid exposure to sunlight or UV light. Nursing mothers.
Antagonizes oral anticoagulants. Antagonized by barbiturates. May potentiate alcohol. Oral contraceptives may be less effective.
Oral thrush, GI distress, dizziness, confusion, peripheral neuritis, photosensitivity, granulocytopenia, leukopenia, proteinuria, lupus-like syndrome.
Tabs 125mg—100; 250mg—100, 500
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds